A protein called PIKfyve impacts multiple processes involved in metabolism and cell death; blocking it is key to making immunotherapy work in prostate cancer.
The new test could signal whether treatment is working months earlier than standard imaging scans, allowing doctors to try alternatives sooner, initial results show.
Activity of the polycomb repressive complex 1 is essential for the development and maintenance of leukemic cells; disrupting it presents a new potential therapeutic approach.
Some prostate tumors transition from being glandular to more nerve-like in response to drugs that block the androgen receptor; a new preclinical study examines the underlyin
Findings offer clues to why some types of renal cell carcinoma respond to immunotherapy while others do not.
Trial will evaluate the safety and efficacy of histotripsy against liver tumors at eight U.S. sites.